

Resource Summary Report

Generated by [nidm-terms](#) on Sep 21, 2026

Therapeutic Structural Antibody Database

RRID:SCR_022093

Type: Tool

Proper Citation

Therapeutic Structural Antibody Database (RRID:SCR_022093)

Resource Information

URL: <http://opig.stats.ox.ac.uk/webapps/newsabdab/therasabdab/search/>

Proper Citation: Therapeutic Structural Antibody Database (RRID:SCR_022093)

Description: Tracks all antibody and nanobody related therapeutics recognized by World Health Organisation, and identifies any corresponding structures in Structural Antibody Database with near exact or exact variable domain sequence matches. Synchronized with SAbDab to update weekly, reflecting new Protein Data Bank entries and availability of new sequence data published by WHO.

Abbreviations: Thera-SAbDab

Resource Type: data or information resource, database

Defining Citation: [DOI:10.1093/nar/gkz827](https://doi.org/10.1093/nar/gkz827)

Keywords: Immunotherapeutics, SAbDab, World Health Organisation, antibodies specific data, weekly sequence alignment

Funding: AstraZeneca ;
Engineering and Physical Sciences Research Council and Medical Research Council ;
F. Hoffmann-La Roche AG ;
GlaxoSmithKline ;
UCB Celltech

Availability: Free, Freely available

Resource Name: Therapeutic Structural Antibody Database

Resource ID: SCR_022093

Record Creation Time: 20220421T050138+0000

Record Last Update: 20260919T195738+0000

Ratings and Alerts

No rating or validation information has been found for Therapeutic Structural Antibody Database.

No alerts have been found for Therapeutic Structural Antibody Database.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Zhou Y, et al. (2023) AB-Amy: machine learning aided amyloidogenic risk prediction of therapeutic antibody light chains. *Antibody therapeutics*, 6(3), 147.

Wilkinson I, et al. (2022) Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names. *mAbs*, 14(1), 2123299.

Akbar R, et al. (2022) Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies. *mAbs*, 14(1), 2008790.

Thorsteinson N, et al. (2021) Structure-based charge calculations for predicting isoelectric point, viscosity, clearance, and profiling antibody therapeutics. *mAbs*, 13(1), 1981805.